Recurrent Head and Neck Squamous Cell Carcinoma Recruiting Phase 1 Trials for Efineptakin alfa (DB16395)

IndicationStatusPhase
DBCOND0057896 (Recurrent Head and Neck Squamous Cell Carcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04588038NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing SurgeryTreatment